Erythropoietin Reduces Neural and Cognitive Processing of Fear in Human Models of Antidepressant Drug Action

Biological Psychiatry

Volumn 62, Issue 11, 2007, Pages 1244-1250

  Miskowiak, Kamilla ^a,b   O'Sullivan, Ursula ^b   Harmer, Catherine J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antidepressant; erythropoietin; fear; fMRI; healthy volunteers

Indexed keywords

ANTIDEPRESSANT AGENT; ERYTHROPOIETIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; EMOTION; FACIAL EXPRESSION; FEAR; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAPPINESS; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NERVE POTENTIAL; NEUROPROTECTION; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT RESPONSE; VISUAL STIMULATION;

ADOLESCENT; ADULT; AFFECT; ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; EMOTIONS; ERYTHROCYTE VOLUME; ERYTHROPOIETIN; FACIAL EXPRESSION; FEAR; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OCCIPITAL LOBE; OXYGEN; PARIETAL LOBE; PHOTIC STIMULATION; RECOGNITION (PSYCHOLOGY);

EID: 35848930155     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.01.011     Document Type: Article

References (46)

1. Manji H.K., Moore G.J., and Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 48 (2000) 740-754
2. Fossati P., Radtchenko A., and Boyer P. Neuroplasticity: From MRI to depressive symptoms. Eur Neuropsychopharmacol 14 (2004) S503-S510
3. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., A Gray N., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53 (2003) 707-742
4. Jacobson L.O., Goldwasser E., Fried W., and Plzak L.F. Studies on erythropoiesis. VII. The role of the kidney in the production of Erythropoietin. Trans Assoc Am Physicians 70 (1957) 305-317
5. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Neurosci 6 (2005) 484-494
6. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97 (2000) 10526-10531
7. Mogensen J., Miskowiak K., Sorensen T.A., Lind C.T., Olsen N.V., Springborg J.B., and Mala H. Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern in normal rats. Pharmacol Biochem Behav 77 (2004) 381-390
8. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
9. Ehrenreich H., Hinze-Selch D., Stawicki S., Aust C., Knolle-Veentjer S., Wilms S., et al. Improvement of cognitive function in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12 (2007) 206-220
10. Viviani B., Bartesaghi S., Corsini E., Villa P., Ghezzi P., Garau A., et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem 93 (2005) 412-421
11. Miskowiak K, O'Sullivan U, Harmer C: Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neuroscience (in press).
12. Harmer C.J., Shelley N.C., Cowen P.J., and Goodwin G.M. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 161 (2004) 1256-1263
13. Harmer C.J., Mackay C.E., Reid C.B., Cowen P.J., and Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59 (2006) 816-820
14. Murphy S.E., Norbury R., Cowen P.J., and Harmer C.J. Imaging the acute effects of citalopram. J Psychopharmacol 20 S (2006) A11
15. Ekman P., and Friesen W.V. Pictures of Facial Affect (1976), Consulting Psychologists Press, Palo Alto, California
16. Woolrich M.W., Ripley B.D., Brady M., and Smith S.M. Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage 14 (2001) 1370-1386
17. Boynton G.M., Engel S.A., Glover G.H., and Heeger D.J. Linear systems analysis of functional magnetic resonance imaging in human V1. J Neurosci 16 (1996) 4207-4221
18. Woolrich M.W., Behrens T.E., Beckmann C.F., Jenkinson M., and Smith S.M. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage 21 (2004) 1732-1747
19. Talairach J., and Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain (1988), Thieme Medical Publishers, New York
20. Lancaster J.L., Woldorff M.G., Parsons L.M., Liotti M., Freitas C.S., Rainey L., et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 10 (2000) 120-131
21. Maldjian J.A., Laurienti P.J., Kraft R.A., and Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19 (2003) 1233-1239
22. Harmer C.J., Hill S.A., Taylor M.J., Cowen P.J., and Goodwin G.M. Toward a neuropsychological theory of antidepressant drug action: Increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry 160 (2003) 990-992
23. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
24. Eysenck H.J., Eysenck S.B.J., and Barrett P. A revised version of the Psychoticism Scale. Pers Individ Dif 6 (1985) 21-29
25. Spielberger C.D. Manual for the State-Trait Anxiety Inventory (STAI) (1983), Consulting Psychologists Press, Palo Alto, California
26. Von Zerssen D., Strian F., and Schwarz D. Evaluation of Depressive States, Especially in Longitudinal Studies (1974), Karger, Basel, Switzerland
27. Watson D., Clark L.A., and Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol 54 (1988) 1063-1070
28. Morris J.S., Frith C.D., Perrett D.I., Rowland D., Young A.W., Calder A.J., et al. A differential neural response in the human amygdala to fearful and happy facial expressions. Nature 383 (1996) 812-815
29. Vuilleumier P., Armony J.L., Driver J., and Dolan R.J. Effects of attention and emotion on face processing in the human brain: An event-related fMRI study. Neuron 30 (2001) 829-841
30. Vuilleumier P., Armony J.L., and Dolan R.J. Reciprocal links between emotion and attention. In: Frackowiak R.J.S., and Mazziotta J. (Eds). Human Brain Function (2004), Elsevier, London 419-444
31. Bouhuys A.L., Geerts E., and Gordijn M.C. Depressed patients' perceptions of facial emotions in depressed and remitted states are associated with relapse. A longitudinal study. J Nerv Ment Dis 187 (1999) 595-602
32. Lawrence N.S., Williams A.M., Surguladze S., Giampietro V., Brammer M.J., Andrew C., et al. Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biol Psychiatry 55 (2004) 578-587
33. Morris J.S., Ohman A., and Dolan R.J. A subcortical pathway to the right amygdala mediating "unseen" fear. Proc Natl Acad Sci U S A 96 (1999) 1680-1685
34. Vuilleumier P., and Pourtois G. Distributed and interactive brain mechanisms during emotion face perception: Evidence from functional neuroimaging. Neuropsychologia 45 (2007) 174-194
35. Vuilleumier P. How brains beware: Neural mechanisms of emotional attention. Trends Cogn Sci 9 (2005) 585-594
36. Rauch S.L., Shin L.M., and Wright C.I. Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci 985 (2003) 389-410
37. Pourtois G., and Vuilleumier P. Dynamics of emotional effects on spatial attention in the human visual cortex. Prog Brain Res 156 (2006) 67-91
38. Williams J.M.G., Watts F.N., MacLeod C., and Mathews A. (1997Cognitive Psychology and Emotional Disorders), Wiley, Chichester, United Kingdom
39. Knutson B., Wolkowitz O.M., Cole S.W., Chan T., Moore E.A., Johnson R.C., et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 155 (1998) 373-379
40. Bonne O., Krausz Y., Aharon Y., Gelfin Y., Chisin R., and Lerer B. Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers. Psychopharmacology 143 (1999) 24-28
41. Wang R., Foniok T., Wamsteeker J.I., Qiao M., Tomanek B., Vivanco R.A., et al. Transient blood pressure changes affect the functional magnetic resonance imaging detection of cerebral activation. Neuroimage 31 (2006) 1-11
42. Ehrenreich H., Degner D., Meller J., Brines M., Behe M., Hasselblatt M., et al. Erythropoietin: A candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 9 (2004) 42-54
43. Hoffbrand A.V., Tuddenham E.G.D., and Catovsky D. Postgraduate Haematology. 5th ed. (2005), Blackwell Publishing, Oxford
44. Ferrario E., Ferrari L., Bidoli P., De Candis D., Del Vecchio M., De Dosso S., et al. Treatment of cancer-related anemia with epoetin alfa: A review. Cancer Treat Rev 30 (2004) 563-575
45. Erbayraktar S., Grasso G., Sfacteria A., Xie Q.W., Coleman T., Kreilgaard M., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100 (2003) 6741-6746
46. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242